Acticor Biotech (XPAR:ALACT) Long-Term Debt : €4.34 Mil (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech Long-Term Debt?

Acticor Biotech's Long-Term Debt for the quarter that ended in Jun. 2023 was €4.34 Mil.

Acticor Biotech's quarterly Long-Term Debt increased from Jun. 2022 (€1.95 Mil) to Dec. 2022 (€7.06 Mil) but then declined from Dec. 2022 (€7.06 Mil) to Jun. 2023 (€4.34 Mil).

Acticor Biotech's annual Long-Term Debt declined from Dec. 2020 (€2.35 Mil) to Dec. 2021 (€2.20 Mil) but then increased from Dec. 2021 (€2.20 Mil) to Dec. 2022 (€7.06 Mil).

Acticor Biotech Long-Term Debt Historical Data

The historical data trend for Acticor Biotech's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acticor Biotech Long-Term Debt Chart

Acticor Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Long-Term Debt

Get a 7-Day Free Trial

0.88

0.92

2.35

2.20

7.06

Acticor Biotech Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Long-Term Debt	Get a 7-Day Free Trial				4.41	2.20	1.95	7.06	4.34

Acticor Biotech (XPAR:ALACT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Acticor Biotech Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Acticor Biotech's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Acticor Biotech (XPAR:ALACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (XPAR:ALACT) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

7V7:Germany

Address

82 Avenue du Maine, Wojo Building, Paris, FRA, 75014

Website

https://www.acticor-biotech.com

Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (XPAR:ALACT) Headlines

No Headlines